Lillie James Woodruff 4

What Happened

• Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics (MPLT), was granted equity awards on February 5, 2026. The filing shows two acquisitions: 7,730 restricted stock units (RSUs) and 31,395 derivative equity units, both reported at an acquisition price of $0 (typical for compensation awards). Combined, the awards total 39,125 units. These are grants/awards rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-02-05; Filing date (Form 4): 2026-02-09 (filed within the usual two-business-day window).
• Reported acquisition amounts and price: 7,730 RSUs @ $0; 31,395 derivative units @ $0. Total units granted = 39,125.
• Vesting/derivative notes:
  • F1/F2: The RSU award (7,730) is a restricted stock unit; each RSU equals the contingent right to one share. Vesting: 1/4 of these RSUs vest on Jan 1, 2027, then 1/16th vest on each subsequent April 1, July 1, October 1 and January 1, subject to continued service.
  • F3: The larger derivative award (31,395) is subject to an option‑style vesting schedule: 1/4 of the total shares underlying the option vests on Feb 5, 2027, then 1/48th vests each month thereafter, subject to continued service.
• Shares owned after the transaction: not specified in the information provided.
• Transaction type code: A = Award/Grant (not a market purchase or sale).

Context

• These are compensation grants (RSUs/options) that vest over time and do not represent an immediate cash purchase or sale; they are standard for employee incentives and do not, by themselves, indicate a trading view. The awards were reported promptly on the Form 4.